S‐1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART‐1501

Thymic carcinoma is a rare epithelial tumor of the thymus with a poor prognosis, and multimodal approaches are important for its treatment. Recently, a number of studies have indicated that S‐1 treatment is effective against thymic carcinoma. S‐1 plus cisplatin with concurrent radiotherapy is a comm...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukuda, Minoru, Funaki, Soichiro, Yamazaki, Takuya, Sato, Shuntaro, Mukae, Hiroshi, Takenoyama, Mitsuhiro, Fukuoka, Junya, Nabeshima, Kazuki, Tateyama, Hisashi, Ashizawa, Kazuto, Hara, Masaki, Seto, Takashi, Okumura, Meinoshin, Sugio, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049479/
https://www.ncbi.nlm.nih.gov/pubmed/32020735
http://dx.doi.org/10.1111/1759-7714.13319
_version_ 1783502449239130112
author Fukuda, Minoru
Funaki, Soichiro
Yamazaki, Takuya
Sato, Shuntaro
Mukae, Hiroshi
Takenoyama, Mitsuhiro
Fukuoka, Junya
Nabeshima, Kazuki
Tateyama, Hisashi
Ashizawa, Kazuto
Hara, Masaki
Seto, Takashi
Okumura, Meinoshin
Sugio, Kenji
author_facet Fukuda, Minoru
Funaki, Soichiro
Yamazaki, Takuya
Sato, Shuntaro
Mukae, Hiroshi
Takenoyama, Mitsuhiro
Fukuoka, Junya
Nabeshima, Kazuki
Tateyama, Hisashi
Ashizawa, Kazuto
Hara, Masaki
Seto, Takashi
Okumura, Meinoshin
Sugio, Kenji
author_sort Fukuda, Minoru
collection PubMed
description Thymic carcinoma is a rare epithelial tumor of the thymus with a poor prognosis, and multimodal approaches are important for its treatment. Recently, a number of studies have indicated that S‐1 treatment is effective against thymic carcinoma. S‐1 plus cisplatin with concurrent radiotherapy is a commonly used treatment for other malignancies, including non‐small cell lung cancer (NSCLC). In addition, its safety has been confirmed, and it has been reported to have a marked effect against thymic carcinoma. Therefore, we conducted a phase II study of S‐1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced thymic carcinoma, in which the overall response rate was employed as the primary endpoint. The secondary endpoints were overall survival, progression‐free survival, and safety.
format Online
Article
Text
id pubmed-7049479
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-70494792020-03-05 S‐1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART‐1501 Fukuda, Minoru Funaki, Soichiro Yamazaki, Takuya Sato, Shuntaro Mukae, Hiroshi Takenoyama, Mitsuhiro Fukuoka, Junya Nabeshima, Kazuki Tateyama, Hisashi Ashizawa, Kazuto Hara, Masaki Seto, Takashi Okumura, Meinoshin Sugio, Kenji Thorac Cancer Original Articles Thymic carcinoma is a rare epithelial tumor of the thymus with a poor prognosis, and multimodal approaches are important for its treatment. Recently, a number of studies have indicated that S‐1 treatment is effective against thymic carcinoma. S‐1 plus cisplatin with concurrent radiotherapy is a commonly used treatment for other malignancies, including non‐small cell lung cancer (NSCLC). In addition, its safety has been confirmed, and it has been reported to have a marked effect against thymic carcinoma. Therefore, we conducted a phase II study of S‐1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced thymic carcinoma, in which the overall response rate was employed as the primary endpoint. The secondary endpoints were overall survival, progression‐free survival, and safety. John Wiley & Sons Australia, Ltd 2020-02-05 2020-03 /pmc/articles/PMC7049479/ /pubmed/32020735 http://dx.doi.org/10.1111/1759-7714.13319 Text en © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Fukuda, Minoru
Funaki, Soichiro
Yamazaki, Takuya
Sato, Shuntaro
Mukae, Hiroshi
Takenoyama, Mitsuhiro
Fukuoka, Junya
Nabeshima, Kazuki
Tateyama, Hisashi
Ashizawa, Kazuto
Hara, Masaki
Seto, Takashi
Okumura, Meinoshin
Sugio, Kenji
S‐1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART‐1501
title S‐1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART‐1501
title_full S‐1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART‐1501
title_fullStr S‐1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART‐1501
title_full_unstemmed S‐1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART‐1501
title_short S‐1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART‐1501
title_sort s‐1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: study protocol of logik1605/jart‐1501
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049479/
https://www.ncbi.nlm.nih.gov/pubmed/32020735
http://dx.doi.org/10.1111/1759-7714.13319
work_keys_str_mv AT fukudaminoru s1pluscisplatinwithconcurrentradiotherapyforlocallyadvancedthymiccarcinomastudyprotocoloflogik1605jart1501
AT funakisoichiro s1pluscisplatinwithconcurrentradiotherapyforlocallyadvancedthymiccarcinomastudyprotocoloflogik1605jart1501
AT yamazakitakuya s1pluscisplatinwithconcurrentradiotherapyforlocallyadvancedthymiccarcinomastudyprotocoloflogik1605jart1501
AT satoshuntaro s1pluscisplatinwithconcurrentradiotherapyforlocallyadvancedthymiccarcinomastudyprotocoloflogik1605jart1501
AT mukaehiroshi s1pluscisplatinwithconcurrentradiotherapyforlocallyadvancedthymiccarcinomastudyprotocoloflogik1605jart1501
AT takenoyamamitsuhiro s1pluscisplatinwithconcurrentradiotherapyforlocallyadvancedthymiccarcinomastudyprotocoloflogik1605jart1501
AT fukuokajunya s1pluscisplatinwithconcurrentradiotherapyforlocallyadvancedthymiccarcinomastudyprotocoloflogik1605jart1501
AT nabeshimakazuki s1pluscisplatinwithconcurrentradiotherapyforlocallyadvancedthymiccarcinomastudyprotocoloflogik1605jart1501
AT tateyamahisashi s1pluscisplatinwithconcurrentradiotherapyforlocallyadvancedthymiccarcinomastudyprotocoloflogik1605jart1501
AT ashizawakazuto s1pluscisplatinwithconcurrentradiotherapyforlocallyadvancedthymiccarcinomastudyprotocoloflogik1605jart1501
AT haramasaki s1pluscisplatinwithconcurrentradiotherapyforlocallyadvancedthymiccarcinomastudyprotocoloflogik1605jart1501
AT setotakashi s1pluscisplatinwithconcurrentradiotherapyforlocallyadvancedthymiccarcinomastudyprotocoloflogik1605jart1501
AT okumurameinoshin s1pluscisplatinwithconcurrentradiotherapyforlocallyadvancedthymiccarcinomastudyprotocoloflogik1605jart1501
AT sugiokenji s1pluscisplatinwithconcurrentradiotherapyforlocallyadvancedthymiccarcinomastudyprotocoloflogik1605jart1501

Ejemplares similares